Clinical Data BMS brings the buzz around late-stage readouts amid a so-so Q1 Pharmaceutical TechnologyBMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Where Gross-to-net Pressure Actually Lives After LaunchNext: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
